Creative Biolabs Expands In Vivo CAR-T Portfolio with Viral and Non-Viral Options

Creative Biolabs, a biotechnology company specializing in cell therapy, has expanded its in vivo CAR-T development portfolio to offer researchers new options for direct immune cell engineering. This update addresses the growing interest in in vivo approaches as alternatives to conventional ex vivo CAR-T development, which often involves complex and resource-intensive steps like cell collection, genetic modification, and manufacturing. The new portfolio includes both viral and non-viral delivery methods, allowing research teams to tailor their strategies based on specific project needs such as target cells, CAR constructs, and preclinical plans.

The company's comprehensive in vivo CAR-T development solution integrates multiple capabilities, from delivery platform selection to functional assessment. For non-viral approaches, Creative Biolabs provides services that explore alternative delivery mechanisms, while its in vivo viral vector-based CAR-T cell development service supports studies using viral vectors. These options are designed to help researchers evaluate different routes and potentially overcome challenges related to targeting and expression control. By offering both viral and non-viral pathways, Creative Biolabs aims to provide flexibility and support for scientists investigating emerging strategies in immune cell engineering, ultimately contributing to the advancement of CAR-T therapies.